Profil bibliographique

Ashish Sanil

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

87Publications signalées

6201Citations signalées

0Affiliations récentes

Domaines associés

Breast Cancer Treatment StudiesAdvanced Breast Cancer TherapiesHER2/EGFR in Cancer ResearchCancer Treatment and PharmacologyPARP inhibition in cancer therapy

Publications récentes

Accès ouvert 2024 supplementary-materials

Supplementary Figure S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery

Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf et autres

0 citations

Accès ouvert 2024 other

Data from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery

Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf et autres

0 citations

Accès ouvert 2024 supplementary-materials

Supplementary Table S3 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery

Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf et autres

0 citations

Accès ouvert 2024 other

Data from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery

Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf et autres

0 citations

Accès ouvert 2024 supplementary-materials

Supplementary Table S4 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery

Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf et autres

0 citations

Accès ouvert 2024 supplementary-materials

Supplementary Figure S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery

Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf et autres

0 citations

Accès ouvert 2024 supplementary-materials

Supplementary Methods S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery

Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf et autres

0 citations

Accès ouvert 2024 supplementary-materials

Supplementary Table S2 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery

Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf et autres

0 citations

Accès ouvert 2024 supplementary-materials

Supplementary Methods S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery

Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf et autres

0 citations

Accès ouvert 2024 supplementary-materials

Supplementary Table S2 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery

Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf et autres

0 citations

Accès ouvert 2024 supplementary-materials

Supplementary Table S4 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery

Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf et autres

0 citations

Accès ouvert 2024 supplementary-materials

Supplementary Table S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery

Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf et autres

0 citations

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Métadonnées interrogées à la demande auprès de OpenAlex (CC0). Sources et limites.